Research
Microbiome therapy shows promise for preventing deadly bloodstream infections in early trial
The Brief
- Researchers at City of Hope and collaborators tested a microbiome therapy in an early trial.
- The therapy delivers 16 selected beneficial bacteria to patients receiving donor stem cell transplants for blood cancers.
- The aim is to prevent dangerous bloodstream infections in these patients.
Why it matters
It is an early trial in a narrow patient group, showing a new way to use live bacterial therapy to prevent serious infections after transplant.
Who’s affected
- Patients receiving donor stem cell transplants for blood cancers
- #microbiome
- #bloodstream infections
- #stem cell transplant
- #clinical trial
- #blood cancer
Researchers at City of Hope and collaborators have pioneered a new approach to preventing dangerous bloodstream infections in patients receiving donor stem cell transplants for blood cancers. The first-of-its-kind therapy delivers 16 carefully selected beneficial bacteria…
Timeline
Medical Xpress reports on the early trial of the microbiome therapy
Medical Xpress - latest medical and health news stories
Microbiome therapy shows promise for preventing deadly bloodstream infections in early trial